IP Library Granted Patent US 11,001,868
Granted Patent B2
US 11,001,868 · App. 15/631,510 · Granted May 11, 2021

Cell-free protein expression using double-stranded concatameric DNA

Inventors: Erik Leeming Kvam (Schenectady, NY); John Richard Nelson (Clifton park, NY); Wei Gao (Clifton Park, NY)
Assignee: Global Life Sciences Solutions Operations UK Ltd
C12P21/00C12P19/34C12P21/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,001,868
App. No.
15/631,510
Granted
May 11, 2021
Kind
B2
Abstract

Methods for in vitro transcription and translation using a double-stranded concatemeric DNA in a eukaryotic cell-free expression system are provided. The method includes the steps of (a) contacting a double-stranded concatemeric DNA with a eukaryotic cell-free expression system, and (b) expressing a protein in vitro from the double-stranded concatemeric DNA in the eukaryotic cell-free expression system. The double-stranded concatemeric DNA includes a plurality of tandem repeat sequences. The plurality of tandem repeat sequences includes an expression sequence including a promoter, a cap-independent translation element (CITE), and an open reading frame. A final concentration of the double-stranded concatemeric DNA in the eukaryotic cell-free expression system is in a range from about 0.1 ng/μL to about 35 ng/μL. A RCA product DNA may be used as the double stranded concatemer DNA for the methods.

Claims (35)

1. A method for in vitro transcription and translation, comprising:

contacting a purified double-stranded concatemeric DNA with a eukaryotic cell-free expression system, wherein the double-stranded concatemeric DNA comprises a plurality of tandem repeat sequences, and wherein each of the plurality of tandem repeat sequences comprises an expression sequence comprising a promoter, a cap-independent translation element (CITE), and an open reading frame; and

expressing a protein in vitro from the double-stranded concatemeric DNA in the eukaryotic cell-free expression system,

wherein a concentration of the double-stranded concatemeric DNA in the eukaryotic cell-free expression system is in a range from about 0.1 ng/μL to about 35 ng/μL.

2. The method of claim 1 , wherein the concentration of the double-stranded concatemeric DNA in the eukaryotic cell-free expression system is in a range from about 0.5 ng/μL to about 20 ng/μL.

3. The method of claim 1 , wherein the concentration of the double-stranded concatemeric DNA in the eukaryotic cell-free expression system is in a range from about 2 ng/μL to about 10 ng/μL.

4. The method of claim 1 , wherein the concentration of the double-stranded concatemeric DNA in the eukaryotic cell-free expression system is in a range from about 3 ng/μL to about 7 ng/μL.

5. The method of claim 1 , wherein the cap-independent translation element(CITE) comprises an internal ribosome entry site (IRES), a translation enhancing element (TEE), or a combination thereof.

6. The method of claim 1 , wherein the open reading frame comprises a codon-optimized sequence for enhancing translation.

7. The method of claim 1 , wherein the open reading frame comprises a tag sequence for purification of the expressed protein, an amino-terminal peptide fusion sequence derived from an IRES for enhanced ribosome recognition, or a combination thereof.

8. The method of claim 1 , wherein the expression sequence further comprises a polyA sequence, a transcriptional termination sequence, an insulator sequence, or a combination thereof.

9. The method of claim 1 , further comprising immobilizing the double-stranded concatemeric DNA onto a substrate prior to contacting the double-stranded concatemeric DNA with the eukaryotic cell-free expression system.

10. The method of claim 9 , further comprising recovering the substrate-immobilized double-stranded concatemeric DNA from the eukaryotic cell-free expression system after expressing the protein in vitro and re-using the recovered substrate immobilized double-stranded concatemeric DNA for a subsequent in vitro transcription and translation reaction.

11. The method of claim 1 , wherein the double-stranded concatemeric DNA is a rolling circle amplification (RCA) product DNA.

12. The method of claim 1 , wherein the double-stranded concatemeric DNA comprises a biotinylated nucleotide, a phosphorothioated nucleotide, an inosine-containing nucleotide, a Locked Nucleic Acid (LNA) nucleotide, a Peptide Nucleic Acid (PNA) nucleotide, 2-amino-deoxyadenosine, 2-thio-deoxythymidine, a polycation nucleotide or a combination thereof.

13. A method for in vitro transcription and translation, comprising:

providing a DNA mini-circle,

generating a double-stranded concatemeric DNA via rolling circle amplification of the DNA mini-circle;

purifying the generated double-stranded concatemeric DNA; and

contacting the purified double-stranded concatemeric DNA with a eukaryotic cell-free expression system in vitro to express a protein from the double-stranded concatemeric DNA via transcription and translation,

wherein a concentration of the double-stranded concatemeric DNA in the eukaryotic cell-free expression system is in a range from about 0.1 ng/μL to 35 ng/μL.

14. The method of claim 13 , wherein the DNA mini-circle consists essentially of a minimalistic expression sequence consisting essentially of a promoter, a cap-independent translation element, and an open reading frame.

15. The method of claim 14 , wherein the minimalistic expression sequence is devoid of any extraneous sequences that are required for propagation of a plasmid in a host cell.

16. The method of claim 14 , wherein the cap-independent translation element (CITE) comprises an internal ribosome entry site (RES), a translation enhancing element (TEE), or a combination thereof.

17. The method of claim 14 , wherein the minimalistic expression sequence further consists essentially of an insulator sequence, a polyA sequence, a transcriptional termination sequence, or a combination thereof.

18. The method of claim 14 , wherein the open reading frame comprises a codon-optimized sequence for enhancing translation, a tag sequence for purification of the expressed protein, an amino-terminal peptide fusion sequence derived from an IRES for enhanced ribosome recognition, or a combination thereof.

19. The method of claim 13 , wherein the concentration of the double-stranded concatemeric DNA in the eukaryotic cell-free expression system is in a range from about 0.5 to 20 ng/μL.

20. The method of claim 13 , wherein the concentration of the double-stranded concatemeric DNA in the eukaryotic cell-free expression system is in a range from about 3 ng/μL to about 7 ng/μL.

21. The method of claim 13 , wherein the double-stranded concatemeric DNA comprises a modified nucleotide, a nucleotide analogue, or a combination thereof.

22. The method of claim 13 , wherein the double-stranded concatemeric DNA comprises a phosphorothioated nucleotide, a biotinylated nucleotide, an inosine-containing nucleotide, a Locked Nucleic Acid (LNA) nucleotide, a Peptide Nucleic Acid (PNA) nucleotide, 2-amino-deoxyadenosine, 2-thio-deoxythymidine, a polycation nucleotide or a combination thereof.

23. The method of claim 13 , further comprising immobilizing the double-stranded concatemeric DNA onto a substrate prior to containing the double-stranded concatemeric DNA with the eukaryotic cell-free expression system.

24. The method of claim 23 , further comprising recovering the substrate-immobilized double-stranded concatemeric DNA from the eukaryotic cell-free expression system after expressing the protein in vitro; and re-using the recovered substrate immobilized double-stranded concatemeric DNA for a subsequent in vitro transcription and translation reaction.

25. The method of claim 13 , wherein the rolling circle amplification is performed using a final concentration of deoxyribonucleotide triphosphates (dNTPs), and optional alpha-thio dNTPs, in a range from about 10 μM to about 10 mM.

26. The method of claim 13 , wherein the rolling circle amplification is performed using a random primer mixture comprising a nucleotide analogue.

27. The method of claim 26 , wherein the random primer mixture has a sequence +N+N(atN)(atN)(atN)*N (SEQ ID NO:6) or 5′-biotin-NNNN*N*N (SEQ ID NO: 7).

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: GE HEALTHCARE UK LIMITED
To: GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD
Reel/Frame 054300/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2020
From: GENERAL ELECTRIC COMPANY
To: GE HEALTHCARE UK LIMITED
Reel/Frame 053981/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2017
From: KVAM, ERIC LEEMING; NELSON, JOHN RICHARD; GAO, WEI
To: GENERAL ELECTRIC COMPANY
Reel/Frame 042797/0508 →
Continuity (1)
Related Publication 20190048379A1 · Feb 14, 2019